The global AI in drug repurposing market, valued at $1.28 billion in 2025, is projected to reach $10.56 billion by 2035 with a CAGR of 23.4%. This growth is driven by the need to accelerate drug discovery, reduce costs, and address chronic and rare diseases. AI technologies like machine learning and NLP enhance drug target identification and clinical data integration, boosting success rates. North America leads the market, while Asia Pacific is the fastest-growing region due to rising healthcare investments and AI adoption.
Stocks saw notable gains driven by specific events: Cynata Therapeutics surged over 800% due to speculative trading without known corporate news; Utz Brands jumped nearly 89% following a $14.25 per share acquisition offer now under shareholder fairne...
Telix Pharmaceuticals published results from the ProstACT SELECT Phase 1 study showing that TLX591-Tx, a targeted radio antibody-drug conjugate therapy for advanced metastatic prostate cancer, is safe and effective when patients are selected using 68...
Strata Critical Medical will release its financial results for the second quarter ending June 30, 2026, on August 4 before the market opens. The company will hold a conference call at 8:00 am Eastern Time the same day, hosted by its Co-CEOs, to discu...
Wintrust Financial reported strong Q2 2026 earnings of $3.30 per share, beating estimates by 4.76%, with revenue of $741.38 million and record net income of $233.70 million. The company showed robust year-over-year growth, with net income up 20% in t...
Roth Capital has reaffirmed its Buy rating on PolyPid following the company's exclusive partnership with Azurity Pharmaceuticals to commercialize D-PLEX100, a drug designed to prevent surgical site infections in the U.S. and Canada. The deal includes...
